Typhoid Fever: Clinical Trials

6 trials for Typhoid Fever, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 36Completed 6
Phase 21Completed 1

Follow Typhoid Fever: new trials by email Literature Review of Typhoid Fever trials Research Report on Typhoid Fever

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants
EuTCV (Vi-CRM Typhoid conjugate vaccine), Typbar-TCV - Typhoid Fever
Phase 2 / Phase 3CompletedEuBiologics Co.,Ltd4442020-09-072021-10-07
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
Vi-DT (Multi-dose formulation), Vi-DT (Single dose formulation), Control Vaccine - Typhoid
Phase 3CompletedInternational Vaccine Institute18002020-02-042021-08-27
Nepal Undifferentiated Febrile Illness Trial
Azithromycin, Co-trimoxazole - Undifferentiated Febrile Illness
Phase 3CompletedOxford University Clinical Research Unit, Vietnam3302016-05-232023-12-06
Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
Typhoid Vi polysaccharide - Salmonella Infections, Typhoid Fever
Phase 3CompletedSanofi Pasteur, a Sanofi Company2002012-05-012014-05-12
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis
Phase 3CompletedNovartis5522011-11-012014-03-11
Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity
Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix - Hepatitis A
Phase 3CompletedGlaxoSmithKline10342002-05-012016-09-09

Narrower conditions

Bacterial Infections (1)  ·  Encephalitis, Japanese (1)  ·  Hepatitis A (1)  ·  Meningitis, Meningococcal (1)  ·  Meningococcal Infections (1)  ·  Rabies (1)  ·  Salmonella Infections (1)  ·  Yellow Fever (1)

Broader conditions

Bacterial Infections and Mycoses (6)  ·  Enterobacteriaceae Infections (6)  ·  Gram-Negative Bacterial Infections (6)  ·  Infections (6)  ·  Bacterial Infections (5)  ·  Salmonella Infections (5)  ·  RNA Virus Infections (2)  ·  Virus Diseases (2)  ·  Arbovirus Infections (1)  ·  Brain Diseases (1)  ·  Central Nervous System Bacterial Infections (1)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Infections (1)  ·  Central Nervous System Viral Diseases (1)  ·  Digestive System Diseases (1)

Interventions

Vi polysaccharide vaccine, typhoid (2)  ·  Azithromycin (1)  ·  Diphtheria Toxoid (1)  ·  Dosage Forms (1)  ·  Japanese Encephalitis Vaccines (1)  ·  MenACWY-CRM vaccine (1)  ·  Rabies Vaccines (1)  ·  Trimethoprim, Sulfamethoxazole Drug Combination (1)  ·  Yellow Fever Vaccine (1)

Sponsors

EuBiologics Co.,Ltd (1)  ·  GlaxoSmithKline (1)  ·  International Vaccine Institute (1)  ·  Novartis (1)  ·  Oxford University Clinical Research Unit, Vietnam (1)  ·  Sanofi Pasteur, a Sanofi Company (1)

Countries

Philippines (2)  ·  Czechia (1)  ·  Germany (1)  ·  Japan (1)  ·  Nepal (1)

Top investigators

Buddha Basnyat, MBBS,MSc,MD (1)  ·  Josefina C Carlos, MD (1)

Results publications

PMID 24873986, PMID 25308927, PMID 28969659, PMID 32991678, PMID 35664443, PMID 36774331